Background and Aims: According to the Japanese Association for Thoracic Surgery, the occurrence of lymphoid tumor among mediastinal tumours is not many: 5.3% in 2000 and 6.4% in 2008. It is said to be difficult to differentiate lymphoid tumor from other mediastinal tumours based only on the image findings.
Thoracic Surgery, the occurrence of lymphoid tumor among mediastinal tumours is not many: 5.3% in 2000 and 6.4% in 2008 . It is said to be difficult to differentiate lymphoid tumor from other mediastinal tumours based only on the image findings.
Methods: We operated on two cases of anterior mediastinal tumours which were eventually diagnosed as malignant lymphoma.
Results: One of the cases was a 50-year-old woman who had undergone operation for sigmoid colon cancer. In a follow up, anterior mediastinal tumor of 15 mm in diameter was detected on chest CT scan. Chest MRI revealed the low intensity mass on T1 imaging, and high intensity on T2 imaging at the anterior mediastinum. We suspected it to be thymoma and performed VATS-thymectomy. The histopathological findings revealed lymphoepithelial lesion, and CD20(+) and CD3(−) by immunostaining. Thus we diagnosed her as MALT lymphoma. There is no report of recurrence 21 months after the operation.
Another case was a 45-year-old woman who was pointed out an abnormal shadow on chest X-ray in a medical check-up. A mass of 10 cm in diameter was detected on chest CT scan and MRI, and we suspected it to be thymoma. As invasion to pericardium and left lung was found during the operation, we performed VATS-extended thymectomy, partial pericardiectomy and left upper lobectomy. The histopathological findings revealed alveolar aggregation of tumor cells. Based on the immunostaining, we diagnosed her as diffuse large B-cell lymphoma. Because surgical margin was partially positive, combined modality therapy has been planned following the operation.
Conclusion:
We experienced two cases of primary thymic malignant lymphoma which were first considered to be thymoma. We will report them with some literature consideration. Background and Aims: Lung cancer is the leading cause of cancer death in Taiwan. The 5-year survival rate was 15.9%, with a median survival of 13.2 months. The prognosis is poor and how to improve the survival remains an important issue. Patient-derived cancer cells are valuable tools for studying the molecular basis of lung cancer and evaluating therapeutic strategies. In this study we develop cell lines directly from lung cancer patients with malignant pleural effusion (MPE) no matter these patients had treatment or not. We hope pharmacological profiling of patient-derived cells could be an efficient way to direct therapeutic choices for individual cancer patients.
Methods:
The MPE samples were consecutively collected from lung cancer patients in National Taiwan University Hospital (NTUH). Primary patient-derived cancer cells were directly cultured from MPE. After successful culture, genetic testing of driver mutation was performed by MALDI -TOF mass spectrometry assay.
Results: Until now total 417 MPE samples with cytology positive of malignant cells were used to generate primary cancer cells. 117 primary cancer cells were successful established (success rate was 28%). These cells include 3 histological subtypes: 2 cells were squamous cell carcinoma, 7 cells were small cell carcinoma and 105 cells were adenocarcinoma. Driver mutation detection of adenocarcinoma was performed by MALDI -TOF mass spectrometry assay. Account of 105 primary cancer cells of adenocarcinoma, 29% was EGFR L858R mutation (8 with T790M mutation), 21% was EGFR exon 19 deletion (5 with T790M mutation), 6% was EGFR exon 20 insertion, 4% was KRAS mutation, 2% was BRAF mutation and 2% was EML4-ALK translocation.
Conclusion:
We successfully established 117 primary cancer cells and performed the driver mutation testing. Most of these cells are derived from patients who failed to chemotherapy or EGFR-TKIs therapy. These cells will be used to study the mechanism of drug resistance and evaluate the therapeutic strategies. Background and Aims: Liver is the most common site of metastasis from small cell lung cancer (SCLC), however, rupture is rare. Here, we describe an autopsy case of SCLC who died of this condition.
Methods:
A 50-year-old male visited our hospital because of an abnormal shadow on a chest X-ray. He complained of dry cough and slight fever for three weeks. He had bulbar conjunctiva, and many petechias on his lower extremities. Laboratory tests revealed anaemia, elevation of hepatic enzymes, and ProGRP. CT scan revealed a mass in the right upper lung lobe, and pleural effusion on both sides. Multiple liver tumours were also detected and some were located at the subcapsular region. Histological examination of the tumor specimen obtained by bronchoscopy confirmed the diagnosis of SCLC, and antitumor chemotherapy was started. Several h after completion of the chemotherapy on day 1, he suddenly complained of nausea and general malaise. Laboratory tests showed anaemia, elevation of hepatic and biliary enzymes, acute renal insufficiency, and hyperpotassemia. Thereafter, his condition deteriorated rapidly, and died the next morning. An autopsy revealed distributed liver metastases with necrosis, subcapsular liver hematoma, and haemorrhagic ascites, and ruptured liver metastases was thought as a cause of death.
Results: Ruptured liver metastases from SCLC is rare, and several contributing factors have been proposed, including hypervascularity, necrotic tendency, subcapsular location, congestion of the local hepatic vein, increased intra-abdominal pressure, coagulopathy, and rapid tumor growth. Our patient had some of these risk factors, and from his clinical course, the chemotherapy was also considered to be one of the triggers of this condition due to tumor necrosis.
Conclusion:
We comprehensively reviewed the literature and found 11 similar cases with this condition. Physicians need to pay attention to this condition, especially after chemotherapy has initiated.
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